Why Legacy in 2024?, page-4

I've been stewing on the Bauloora assay results as well. They really should have been back by now. Theoretically they can't sit on the results too long under the continuous disclosure obligations. So if there is news to share then I think we're all ears.

Also wondering about their Securities Trading Policy announcement. You'd have thought this would /should already have been in place but maybe as a small company that's gaining traction they just hadn't yet formalised these internal policies. I suspect there's also an element of wanting to give the market confidence they have a solid handle on managing conflict of interest and insider trading. Junior explorers can get pretty leaky at times. Also, Newmont looking over their shoulder may also have had something to do with Legacy getting this published.

Either way, the waiting game continues...